Who Paid My Doc
A Phase 1, Single-Arm, Open-Label, Multiple-Dose Study to Assess the Pharmacokinetics of Rifaximin Soluble Solid Dispersion Formulation in Adults Subjects with Impaired Hepatic Function and Healthy Matched Subjects as Controls
Research payments
$718,401
Through program year 2024, $718,401 in research payments was reported against A Phase 1, Single-Arm, Open-Label, Multiple-Dose Study to Assess the Pharmacokinetics of Rifaximin Soluble Solid Dispersion Formulation in Adults Subjects with Impaired Hepatic Function and Healthy Matched Subjects as Controls, across 7 payments, paid by Bausch Health US, LLC.
- Paid by
- Bausch Health US, LLC
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $306,703 | 3 |
| 2023 | Research | $411,698 | 4 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
1 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.